Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTHAR Therapy for CNS Sarcoidosis
NCT02920710Phase 4Withdrawn
- Sponsor
- Cleveland Clinic
- Start
- Feb 2019
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of repository corticotropin injection in neurosarcoidosis, sponsored by Cleveland Clinic. Primary endpoint: Proportion of patients with clinically significant improvement - successful glucocorticoid tapering at 12 weeks. Planned start Feb 2019; status: withdrawn.
02
Drugs
repository corticotropin injection
03
Conditions
neurosarcoidosis
Beyond the preview
Go deeper on NCT02920710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920710.